Kurma Partners

Brink Therapeutics is a biotechnology research firm specializing in cell therapy development. It focuses on using reprogrammed recombinases, a type of enzyme that can alter DNA, to create innovative therapies. The company's proprietary technology, designed for in-vivo cell and gene therapy, mimics natural selection to enhance proteins and accelerate testing of recombinases. This enables researchers to develop more efficient and controlled therapies for complex diseases, including cancer and inherited conditions.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.